

April 24, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Clarification on news item appearing in “Media/Publication”

Ref: NSE/CM/Surveillance/16905

This is in with reference to your e-mail dated April 23, 2026 and in relation to a news item appearing in "<https://www.cnbctv18.com/>" on April 23, 2026 captioned "Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say.

In this connection, we wish to inform that the above captioned news item headline is correct, as the Company has not yet received approval ('Notice of Compliance') for its Semaglutide Injection from Health Canada. We further wish to inform that as part of the regulatory review process, the Company has received the 'Drug Identification Numbers (DINs)' for Semaglutide Injection from Health Canada on April 22, 2026. We continue to engage constructively with the regulatory authority and remain committed to bringing the product to the Canadian market upon approval.

Further, as required, please take on record below clarifications on the following points:

- *Whether such negotiations were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations till date - Not applicable.*
- *Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015 – Please refer above. At this stage, there is no material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations.*
- *The material impact of this article on the Company – We believe there is no material impact of the above referred news article on the Company captioned "Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say", as the Company has not yet received approval ('Notice of Compliance') for its Semaglutide Injection from Health Canada.*

Considering the material price movement in the shares of the Company on April 23, 2026, the Company has, on its own, provided required clarification to stock exchanges on the above referred news article, in compliance with Regulation 30 of the SEBI Listing Regulations.

Further note that in compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations.

This is for your information and records.

Thanking you,

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

K Randhir Singh

Company Secretary, Compliance Officer and Head-CSR